Disclosed herein, are compositions, methods, systems, and apparatus for collecting biological material from the nasal cavity of a subject or the olfactory region of a subject's nasal cavity. In some embodiments, the biological material is collected from a targeted sub-region of the nasal cavity, such as a targeted sub-region of the olfactory region, wherein such biological material is specific to the targeted sub-region. In some embodiments, the biological material collected from a targeted sub-region is preserved according to its localization. In some embodiments, the biological material comprises cerebrospinal fluid, one or more microbes of the patient's microbiome, one or more components of the patient's metabolome, one or more pathogens, and/or one or more biomarkers of interest. In some embodiments, a specific formulation is delivered to the region in the nasal cavity for facilitating biological material collection located therein.

The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

Methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

The present disclosure relates to the field of immunology, in particular to a B-cell epitope of Trichinella spiralis cysteine protease inhibitor, a hybridoma cell line, a monoclonal antibody and uses thereof. The present disclosure provides a hybridoma cell line that can generate anti-WN10 antibody, and identifies the specific B-cell epitope of WN10 protein recognized by the monoclonal antibody. These are of great significance for the diagnosis of trichinellosis, for the establishment of competitive ELISA for detecting antibodies and sandwich ELSIA for detecting circulating antigens, for the detection of Trichinella spiralis in different hosts and for the development of subunit vaccines.

Provided is a measurement method with which an analyte in a sample containing a high concentration of the analyte can be measured with high accuracy without diluting the sample in multiple stages. An embodiment of the present invention relates to a measurement method for measuring an amount of an analyte in a sample, the method including: a binding step of providing the sample to a containing part of a measuring chip including the containing part for containing liquid, and a first capture body immobilized inside the containing part and having a recognition site that specifically binds to the analyte so as to bind the analyte contained in the sample to the first capture body; and a measurement step of measuring an amount of the analyte bound to the first capture body. The measurement method includes an adjustment step in which a second capture body having a recognition site that specifically binds to the analyte is bound to a part of the analyte in the sample in parallel with the binding step or before the binding step so as to reduce the amount of the analyte capable of binding to the first capture body.

The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.

Compositions and methods for detecting food-based allergens on a surface are disclosed. A composition can include ninhydrin and a protease enzyme. The protease enzyme can be a cysteine protease enzyme, an aspartic protease enzyme, or combinations thereof. In some embodiments, the composition can include a carrier. Methods of detecting a food-based allergen on a surface can include providing a composition including ninhydrin and providing a protease enzyme. The method can include applying the composition and the protease enzyme to the surface. The method can also include allowing the ninhydrin and the protease enzyme to interact with particulates from the surface for a detection period. Detecting the food-based allergen can occur when the composition changes color after the detection period.

The present invention relates to a method for predicting a response to a treatment of an eye disease on the basis of proteome changes. The invention also relates to a kit for use the method.

The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.